Citizens lowered the firm’s price target on Sagimet Biosciences (SGMT) to $12 from $35 and keeps an Outperform rating on the shares. Sagimet Biosciences is advancing denifanstat into a Phase 3 acne trial in 2H26 with pivotal data expected by year-end 2027, while next-generation FASN inhibitor TVB-3567 provides additional clinical and intellectual property upside, supporting a strategic shift into a large, under-innovated acne market with blockbuster revenue potential, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Options Volatility and Implied Earnings Moves This Week, May 18 – May 22, 2026
- SGMT Upcoming Earnings Report: What to Expect?
- Sagimet Biosciences price target lowered to $28 from $37 at Clear Street
- Sagimet Maintained at Buy as Strong Cash Runway and Advancing Acne Franchise Support Unchanged $28 Price Target
- Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)